A Longitudinal Study of the Changes in Body Fat and Metabolic Parameters in a South African Population of HIV-Positive Patients Receiving an Antiretroviral Therapeutic Regimen Containing Stavudine
Restricted accessResearch articleFirst published online August, 2009
A Longitudinal Study of the Changes in Body Fat and Metabolic Parameters in a South African Population of HIV-Positive Patients Receiving an Antiretroviral Therapeutic Regimen Containing Stavudine
The aim of this study was to determine the patterns of change in body fat and metabolic parameters in a South African cohort on a first line ART regimen containing stavudine. Fasting lipogram, blood glucose and insulin levels, CD4 cell count, viral load, BMI, waist-to-hip ratio (WHR), and skinfold thickness at the triceps, scapula, and iliac crest were measured before starting ART in 42 (27 female) subjects. Repeat measurements were performed at four monthly intervals for 2 years. Lipodystrophy was diagnosed using patient perception and assessment by a physician. At baseline, subjects who went on to develop lipodystrophy (LD group) were fatter and had higher skinfold thickness at all three sites and higher insulin levels than subjects who never developed lipodystrophy (NLD group). The WHR increased to a greater extent while hip circumference and tricep skinfolds fell more significantly in the LD than NLD group. Triglyceride and cholesterol levels increased significantly in both groups while lactate and glucose levels increased more and insulin levels increased less in the LD than the NLD group. Neither viral load nor CD4 count differed between the groups during the study. Viral load correlated positively with insulin levels at baseline. Thus, lipodystrophy in the South African population is characterized by a higher BMI before initiation of ART and lipoatrophy of the arms and hips, lipohypertrophy of the waist, and increased lactate production. When compared to the NLD group, the LD subjects display attenuated insulin secretory output in response to a higher weight gain.
Get full access to this article
View all access options for this article.
References
1.
CarrA, SamarasK, BurtonSet al.A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998; 12:F51–F58.
2.
GrinspoonS, CarrA. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med, 2005; 352:48–62.
3.
CurrierJS, HavlirDV. Complications of HIV disease and therapy. Top HIV Med, 2008; 16:23–30.
4.
BoulleA, OrrelC, KaplanRet al.Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther, 2007; 12:753–760.
5.
van GriensvenJ, De NaeyerL, MushiTet al.High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg, 2007; 101:793–798.
6.
Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report. Geneva: WHO, 2008. http://www.who.int/hiv/mediacentre/2008progressreport/en/index.html(accessed on December 11th, 2008).
7.
South African national antiretroviral treatment guidelines1st ed.. Pretoria: National Department of Health, 2004. http://www.doh.gov.za/docs/factsheets/guidelines/artguidelines04/intro.pdf(accessed on December 11th, 2008).
8.
Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Towards universal access. Geneva: WHO, 2006. http://www.who.int/hiv/pub/guidelines/adult/en/index.html(accessed on December 11th, 2008).
9.
BeckEJ, VitoriaM, MandaliaS, CrowleyS, GilksCF, SouteyrandY. National adult antiretroviral therapy guidelines in resource-limited countries: Concordance with 2003 WHO guidelines?AIDS, 2006; 20:1471–1479.
10.
Renaud-ThéryF, NguimfackBD, VitoriaMet al.Use of antiretroviral therapy in resource-limited countries in 2006: Distribution and uptake of first- and second-line regimens. AIDS, 2007; 21,Suppl 4:S89–S95.
11.
LichtensteinKA, WardDJ, MoormanACet al.Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS, 2001; 15:1389–1398.
12.
WangJ, ThorntonJC, KolesnikS, PiersonRNJr. Anthropometry in body composition. An overview. Ann NY Acad Sci, 2000; 904:317–326.
13.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18:499–502.
14.
MatthewsDR, HoskerJP, RudenskiAS, NaylorBA, TreacherDF, TurnerRC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
15.
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc, 2001; 285:2486–2497.
16.
HeathKV, HoggRS, SingerJ, ChanKJ, O'ShaughnessyMV, MontanerJS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr., 2002; 30:440–447.
17.
JonesR, SawleshwarkarS, MichailidisCet al.Impact of antiretroviral choice on hypercholesterolaemia events: The role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med, 2005; 6:396–402.
18.
BrownTT, LiX, ColeSRet al.Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS, 2005; 19:1375–1383.
19.
MutimuraE, StewartA, RheederP, CrowtherNJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 2007; 46:451–455.
20.
MillerJ, CarrA, SmithDet al.Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS, 2000; 14:2406–2407.
21.
HeathKV, HoggRS, ChanKJet al.Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS, 2001; 15:231–239.
22.
BacchettiP, GripshoverB, GrunfeldCet al.Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr, 2005; 40:121–131.
23.
From the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr, 2006; 42:562–571.
24.
PujariSN, DravidA, NaikEet al.Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr, 2005; 39:199–202.
25.
CarrA, SamarasK, ThorisdottirA, KaufmannGR, ChisholmDJ, CooperDA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet, 1999; 353:2093–2099.
26.
PaceCS, MartinAM, HammondEL, MamotteCD, NolanDA, MallalSA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther, 2003; 8:323–331.
27.
HamdyO, PorramatikulS, Al-OzairiE. Metabolic obesity: The paradox between visceral and subcutaneous fat. Curr Diabetes Rev, 2006; 2:367–373.
28.
TchkoniaT, GiorgadzeN, PirtskhalavaTet al.Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol, 2002; 282:R1286–1296.
29.
DroletR, RichardC, SnidermanADet al.Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond), 2008; 32:283–291.
HocquelouxL, AlbertiC, FeugeasJPet al.Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV Med, 2003; 4:18–23.
32.
BrinkmanK, ter HofstedeHJ, BurgerDM, SmeitinkJA, KoopmansPP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS, 1998; 12:1735–1744.
33.
McComseyGA, PaulsenDM, LonerganJTet al.Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS, 2005; 19:15–23.
34.
CherryCL, LalL, ThompsonKAet al.Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr, 2005; 38:263–267.
35.
LonerganJT, BarberRE, MathewsWC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS, 2003; 17:2495–2499.
36.
BolhaarMG, KarstaedtAS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis, 2007; 45:254–260.
37.
CameronDW, da SilvaBA, ArribasJRet al.A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis, 2008; 198:234–240.
38.
TashimaKT, BaussermanL, AltEN, AznarE, FlaniganTP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials, 2003; 4:29–36.
39.
McGuinnessOP. Defective glucose homeostasis during infection. Annu Rev Nutr, 2005; 25:9–35.
40.
El-SadrWM, MullinCM, CarrAet al.Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naive cohort. HIV Med, 2005; 6:114–121.
41.
HommesMJ, RomijnJA, EndertE, Eeftinck SchattenkerkJK, SauerweinHP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism, 1991; 40:651–656.
42.
HeyligenbergR, RomijnJA, HommesMJ, EndertE, Eeftinck SchattenkerkJK, SauerweinHP. Non-insulin-mediated glucose uptake in human immunodeficiency virus-infected men. Clin Sci (Lond), 1993; 84:209–216.
43.
RoseH, WoolleyI, HoyJet al.HIV infection and high-density lipoprotein: The effect of the disease vs the effect of treatment. Metabolism, 2006; 55:90–95.
44.
GuaraldiG, MurriR, OrlandoGet al.Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials, 2003; 4:99–106.
45.
SantosJ, PalaciosR, RuizJ, GonzálezM, MárquezM. Study of patients diagnosed with advanced HIV in the HAART era–OMEGA Cohort. Int J STD AIDS, 2005; 16:252–255.
46.
CarrA, EmeryS, LawM, PulsR, LundgrenJD, PowderlyWG. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet, 2003; 361:726–735.
47.
AsensiV, Martín-RocesE, CollazosJet al.Association between physical and echographic fat thickness assessments and a lipodystrophy grading scale in lipodystrophic HIV patients: Their practical implications. AIDS Res Hum Retroviruses, 2006; 22:830–836
48.
TienPC, GrunfeldC. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis, 2004; 17:27–32.
49.
SeftelHC, AsvatMS, JoffeBIet al.Selected risk factors for coronary heart disease in male scholars from the major South African population groups. S Afr Med J, 1993; 83:891–897.
50.
NaranNH, ChettyN, CrowtherNJ. The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis, 2008; 196:155–163.
51.
van der MerweMT, CrowtherNJ, SchlaphoffGP, GrayIP, JoffeBI, LönnrothPN. Evidence for insulin resistance in black women from South Africa. Int J Obes Relat Metab Disord, 2000; 24:1340–1346.
52.
FerrisWF, NaranNH, CrowtherNJ, RheederP, van der MerweL, ChettyN. The relationship between insulin sensitivity and serum adiponectin levels in 3 population groups. Horm Metab Res, 2005; 37:695–701.
53.
MotalaAA, OmarMA, PirieFJ. Diabetes in Africa. Epidemiology of type 1 and type 2 diabetes in Africa. J Cardiovasc Risk., 2003; 10:77–83.
54.
HaugaardSB, AndersenO, HalsallI, IversenJ, HalesCN, MadsbadS. Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution. Metabolism, 2007; 56:939–946.
55.
HaugaardSB, AndersenO, VolundAet al.Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Oxf), 2005; 62:354–361.
